Membrane-type I matrix metalloproteinase-dependent ectodomain shedding of mucin16/CA-125 on ovarian cancer cells modulates adhesion and invasion of peritoneal mesothelium

Biological Chemistry

Volumn 395, Issue 10, 2014, Pages 1221-1231

  Bruney, Lana ^a,b   Conley, Kaitlynn C ^a   Moss, Natalie M ^c   Liu, Yueying ^a   Stack, M Sharon ^a  

^a UNIVERSITY OF NOTRE DAME   (United States)

^b University of Missouri   (United States)

^c United States Patent and Technology Office   (United States)

Author keywords

Biomarker; Meso mimetic; Metastasis; MMP 14; Proteolysis

Indexed keywords

CA 125 ANTIGEN; GLYCOPROTEIN; MATRIX METALLOPROTEINASE 14; MUCIN; MUCIN16; UNCLASSIFIED DRUG; MEMBRANE PROTEIN; MMP14 PROTEIN, HUMAN; MUC16 PROTEIN, HUMAN;

ANIMAL CELL; CANCER CELL; CELL ADHESION; CELL INVASION; CONFERENCE PAPER; CONTROLLED STUDY; EX VIVO STUDY; EXPLANT; FEMALE; FLUORESCENCE MICROSCOPY; HUMAN; HUMAN CELL; IMMUNOREACTIVITY; MESOTHELIUM CELL; MOLECULAR WEIGHT; NONHUMAN; OVARIAN CANCER CELL LINE; PERITONEUM; PERITONEUM ADHESION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCANNING ELECTRON MICROSCOPY; TISSUE MICROARRAY; ANIMAL; C57BL MOUSE; CANCER TRANSPLANTATION; GENETICS; MESOTHELIOMA; METABOLISM; METASTASIS; MOUSE; OVARY TUMOR; PATHOLOGY; PERITONEAL CAVITY; PHYSIOLOGY; TUMOR CELL LINE; TUMOR INVASION;

ANIMALS; CA-125 ANTIGEN; CELL ADHESION; CELL LINE, TUMOR; FEMALE; HUMANS; MATRIX METALLOPROTEINASE 14; MEMBRANE PROTEINS; MICE; MICE, INBRED C57BL; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOPLASM TRANSPLANTATION; NEOPLASMS, MESOTHELIAL; OVARIAN NEOPLASMS; PERITONEAL CAVITY;

EID: 84926486395     PISSN: 14316730     EISSN: 14374315     Source Type: Journal    
DOI: 10.1515/hsz-2014-0155     Document Type: Conference Paper

References (55)

1. Ahmed, N., Riley, C., Rice, G., and Quinn, M. (2005). Role of integrin receptors for fibronectin, collagen and laminin in the regulation of ovarian carcinoma functions in response to a matrix microenvironment. Clin. Exp. Metastasis 22, 391-402.
2. Auersperg, N., Pan, J., Grove, B.D., Peterson, T., Fisher, J., Maines-Bandiera, S., Somasiri, A., and Roskelley, C.D. (1999). E-cadherin induces mesenchymal-to-epithelial transition in human ovarian surface epithelium. Proc. Natl. Acad. Sci. USA 96, 6249-6254.
3. Auersperg, N., Wong, A.S., Choi, K.C., Kang, S.K., and Leung, P.C. (2001). Ovarian surface epithelium: biology, endocrinology, and pathology. Endocr. Rev. 22, 255-288.
4. Barbolina, M.V., Adley, B.P., Ariztia, E.V., Liu, Y., and Stack, M.S. (2007). Microenvironmental regulation of membrane type 1 matrix metalloproteinase activity in ovarian carcinoma cells via collagen-induced EGR1 expression. J. Biol. Chem. 282, 4924-4931.
5. Barbolina, M.V., Moss, N.M., Westfall, S.D., Liu, Y., Burkhalter, R.J., Marga, F., Forgacs, G., Hudson, L.G., and Stack, M.S. (2009). Microenvironmental regulation of ovarian cancer metastasis. Cancer Treat. Res. 149, 319-334.
6. Barbolina, M.V., Liu, Y., Gurler, H., Kim, M., Kajdacsy-Balla, A.A., Rooper, L.,Shepard, J., Weiss, M., Shea, L.D., Penzes, P., et al. (2013). Matrix rigidity activates Wnt signaling through downregulation of Dickkopf-1 protein. J. Biol. Chem. 288, 141-151.
7. Bast, R.C., Klug, T.L., St John, E., Jenison, E., Niloff, J.M., Lazarus, H., Berkowitz, R.S., Leavitt, T., Griffiths, C.T., Parker, L., et al. (1983). A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N. Engl. J. Med. 309, 883-887.
8. Berns, E.M.J.J. and Bowtell, D.D. (2012). The changing view of high-grade serous ovarian cancer. Cancer Res. 72, 2701-2704.
9. Burleson, K.M., Casey, R.C., Skubitz, K.M., Pambuccian, S.E., Oegema, T.R., and Skubitz, A.P.N. (2004a). Ovarian carcinoma ascites spheroids adhere to extracellular matrix components and mesothelial cell monolayers. Gynecol. Oncol. 93, 170-181.
10. Burleson, K.M., Hansen, L.K., and Skubitz, A.P.N. (2004b). Ovarian carcinoma spheroids disaggregate on type I collagen and invade live human mesothelial cell monolayers. Clin. Exp. Metastasis. 21, 685-697.
11. Cannistra, S.A. (2004). Cancer of the ovary. N. Engl. J. Med. 351, 2519-2529.
12. Casey, R.C., Burleson, K.M., Skubitz, K.M., Pambuccian, S.E., Oegema, T.R., Ruff, L.E., and Skubitz, A.P. (2001). Beta 1-integrins regulate the formation and adhesion of ovarian carcinoma multicellular spheroids. Am. J. Pathol. 159, 2071-2080.
13. Chen, S.-H., Hung, W.-C., Wang, P., Paul, C., and Konstantopoulos, K. (2013). Mesothelin binding to CA125/MUC16 promotes pancreatic cancer cell motility and invasion via MMP-7 activation. Sci. Rep. 3, 1870.
14. Cramer, D.W., Bast, R.C., Berg, C.D., Diamandis, E.P., Godwin, A.K., Hartge, P., Hartge P, Lokshin, A.E., Lu, K.H., McIntosh, M.W., et al. (2011). Ovarian cancer biomarker performance in prostate, lung, colorectal, and ovarian cancer screening trial specimens. Cancer Prev. Res. (Phila.) 4, 365-374.
15. Desgrosellier, J.S. and Cheresh, D.A. (2010). Integrins in cancer: biological implications and therapeutic opportunities. Nat. Rev. Cancer 10, 9-22.
16. Devine, P.L., McGuckin, M.A., and Ward, B.G. (1992). Circulating mucins as tumor markers in ovarian cancer (review). Anticancer Res. 12, 709-717.
17. Doi, T., Maniwa, Y., Tanaka, Y., Tane, S., Hashimoto, S., Ohno, Y., Nishio, W., Nishimura, Y., Ohbayashi, C., Okita, Y., et al. (2011). MT1-MMP plays an important role in an invasive activity of malignant pleural mesothelioma cell. Exp. Mol. Pathol. 90, 91-96.
18. Dubeau, L. (2008). The cell of origin of ovarian epithelial tumours. Lancet Oncol. 9, 1191-1197.
19. Egeblad, M. and Werb, Z. (2002). New functions for the matrix metalloproteinases in cancer progression. Nat. Rev. Cancer 2, 161-174.
20. Ellerbroek, S.M., Wu, Y.I., Overall, C.M., and Stack, M.S. (2001). Functional interplay between type I collagen and cell surface matrix metalloproteinase activity. J. Biol. Chem. 276, 24833-28342.
21. Fathalla, M.F. (1971). Incessant ovulation - a factor in ovarian neoplasia? Lancet ii, 163.
22. Goodell, C.A., Belisle, J.A., Gubbels, J.A., Migneault, M., Rancourt, C., Connor, J., Kunnimalaiyaan, M., Kravitz, R., Tucker, W., Zwick, M., et al. (2009). Characterization of the tumor marker muc16 (ca125) expressed by murine ovarian tumor cell lines and identification of a panel of cross-reactive monoclonal antibodies. J. Ovarian Res. 2, 8.
23. Gubbels, J.A.A., Belisle, J., Onda, M., Rancourt, C., Migneault, M., Ho, M., Bera, T.K., Connor, J., Sathyanarayana, B.K., Lee, B., et al. (2006). Mesothelin-MUC16 binding is a high affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors. Mol. Cancer 5, 50.
24. Hillier, S.G. (2012). Nonovarian origins of ovarian cancer. Proc. Natl. Acad. Sci. USA 109, 3608-3609.
25. Howlader, N., Noone, A., Krapcho, M., Garshell, J., Neyman, N., Altekruse, S., Kosary, C.L., Yu, M., Ruhl, J., Tatalovich, Z., et al., eds. (2013). SEER Cancer Statistics Review, 1975-2010 (Bethesda, MD: National Cancer Institute).
26. Hudson, L.G., Zeineldin, R., and Stack, M.S. (2008). Phenotypic plasticity of neoplastic ovarian epithelium: unique cadherin profiles in tumor progression. Clin. Exp. Metastasis 25, 643-655.
27. Husseinzadeh, N. (2011). Status of tumor markers in epithelial ovarian cancer has there been any progress? A review. Gynecol. Oncol. 120, 152-157.
28. Jemal, A., Bray, F., and Ferlay, J. (2011). Global cancer statistics. CA Cancer J. Clin. 61, 69-90.
29. Kaimal, R., Aljumaily, R., Tressel, S.L., Pradhan, R.V., Covic, L., Kuliopulos, A., Zarwan, C., Kim, Y.B., Sharifi, S., and Agarwal, A. (2013). Selective blockade of matrix metalloprotease-14 with a monoclonal antibody abrogates invasion, angiogenesis, and tumor growth in ovarian cancer. Cancer Res. 73, 2457-2467.
30. Kaneko, O., Gong, L., Zhang, J., Hansen, J.K., Hassan, R., Lee, B., and Ho, M. (2009). A binding domain on mesothelin for CA125/ MUC16. J. Biol. Chem. 284, 3739-3749.
31. Kim, J., Coffey, D.M., Creighton, C.J., Yu, Z., Hawkins, S.M., and Matzuk, M.M. (2012). High-grade serous ovarian cancer arises from fallopian tube in a mouse model. Proc. Natl. Acad. Sci. USA 109, 3921-3926.
32. Kui Wong, N., Easton, R.L., Panico, M., Sutton-Smith, M., Morrison, J.C., Lattanzio, F.A., Morris, H.R., Clark, G.F., Dell, A., and Patankar, M.S. (2003). Characterization of the oligosaccharides associated with the human ovarian tumor marker CA125. J. Biol. Chem. 278, 28619-28634.
33. Lengyel, E., Burdette, J.E., Kenny, H.A., Matei, D., Pilrose, J., Haluska, P., Nephew, K.P., Hales, D.B., and Stack, M.S. (2013). Epithelial ovarian cancer experimental models. Oncogene 1-15. DOI: 10.1038/onc.2013.321 [Epub ahead of print].
34. Lessan, K., Aguiar, D.J., Oegema, T., Siebenson, L., and Skubitz, A.P. (1999). CD44 and beta1 integrin mediate ovarian carcinoma cell adhesion to peritoneal mesothelial cells. Am. J. Pathol. 154, 1525-1537.
35. Mai, P.L., Wentzensen, N., and Greene, M.H. (2011). Challenges related to developing serum-based biomarkers for early ovarian cancer detection. Cancer Prev. Res. (Phila.) 4, 303-306.
36. Marth, C., Fuith, L.C., Böck, G., and Dapunt, O. (1989). Modulation of ovarian carcinoma tumor marker CA-125 by γ modulation of ovarian carcinoma tumor marker CA-125 by 7-interferon. Cancer Res. 105, 6538-6542.
37. Marth, C., Egle, D., Auer, D., Rössler, J., Zeimet, A.G., Vergote, I., and Daxenbichler, G. (2007). Modulation of CA-125 tumor marker shedding in ovarian cancer cells by erlotinib or cetuximab. Gynecol. Oncol. 105, 716-721.
38. Moore, R.G., MacLaughlan, S., and Bast, R.C. (2010). Current state of biomarker development for clinical application in epithelial ovarian cancer. Gynecol. Oncol. 116, 240-245.
39. Moser, T.L., Pizzo, S.V., Bafetti, L.M., Man, D.A.F., and Sharon, M. (1996). Evidence for preferential adhesion of ovarian epithelial carcinoma cells to type I collagen mediated by the alpha2beta1 integrin. Int. J. Cancer 701, 695-701.
40. Moss, N.M., Barbolina, M.V., Liu, Y., Sun, L., Munshi, H.G., and Stack, M.S. (2009a). Ovarian cancer cell detachment and multicellular aggregate formation are regulated by membrane type 1 matrix metalloproteinase: a potential role in I.p. metastatic dissemination. Cancer Res. 69, 7121-7129.
41. Moss, N.M., Wu, Y.I., Liu, Y., Munshi, H.G., and Stack, M.S. (2009b). Modulation of the membrane type 1 matrix metalloproteinase cytoplasmic tail enhances tumor cell invasion and proliferation in three-dimensional collagen matrices. J. Biol. Chem. 284, 19791-19799.
42. Patankar, M.S., Jing, Y., Morrison, J.C., Belisle, J.A., Lattanzio, F.A., Deng, Y., Wong, N.K., Morris, H.R., Dell, A., and Clark, G.F. (2005). Potent suppression of natural killer cell response mediated by the ovarian tumor marker CA125. Gynecol. Oncol. 99, 704-713.
43. Rump, A., Morikawa, Y., Tanaka, M., Minami, S., Umesaki, N., Takeuchi, M., and Miyajima, A. (2004). Binding of ovarian cancer antigen CA125/MUC16 to mesothelin mediates cell adhesion. J. Biol. Chem. 279, 9190-9198.
44. Sakata, K., Shigemasa, K., Nagai, N., and Ohama, K. (2000). Expression of matrix metalloproteinases (MMP-2, MMP-9, MT1-MMP) and their inhibitors (TIMP-1, TIMP-2) in common epithelial tumors of the ovary. Int. J. Oncol. 17, 673-381.
45. Scholler, N. and Urban, N. (2007). CA125 in ovarian cancer. Biomark. Med. 1, 513-523.
46. Scholler, N., Garvik, B., Hayden-Ledbetter, M., Kline, T., and Urban, N. (2007). Development of a CA125-mesothelin cell adhesion assay as a screening tool for biologics discovery. Cancer Lett. 247, 130-136.
47. Sounni, N.E., Devy, L., Hajitou, A., Frankenne, F., Munaut, C., Gilles, C., Deroanne, C., Thompson, E.W., Foidart, J.M., and Noel, A. (2002). MT1-MMP expression promotes tumor growth and angiogenesis through an up-regulation of vascular endothelial growth factor expression. FASEB J. 16, 555-564.
48. Strauss, R., Li, Z.-Y., Liu, Y., Beyer, I., Persson, J., Sova, P., Möller, T., Pesonen, S., Hemminki, A., Hamerlik, P., et al. (2011). Analysis of epithelial and mesenchymal markers in ovarian cancer reveals phenotypic heterogeneity and plasticity. PLoS One 6, e16186.
49. Strobel, T. and Cannistra, S.A. (1999). Beta1-integrins partly mediate binding of ovarian cancer cells to peritoneal mesothelium in vitro. Gynecol. Oncol. 73, 362-367.
50. Thériault, C., Pinard, M., Comamala, M., Migneault, M., Beaudin, J., Matte, I., Boivin, M., Piché, A., and Rancourt C. (2011). MUC16 (CA125) regulates epithelial ovarian cancer cell growth, tumorigenesis and metastasis. Gynecol. Oncol. 121, 434-443.
51. Tuxen, M.K., Sölétormos, G., and Dombernowsky, P. (1995). Tumor markers in the management of patients with ovarian cancer. Cancer Treat. Rev. 21, 215-245.
52. Vergote, I.B., Onsrud, M., Børmer, O.P., Sert, B.M., and Moen, M. (1992). CA125 in peritoneal fluid of ovarian cancer patients. Gynecol. Oncol. 44, 161-165.
53. Yin, B.W. and Lloyd, K.O. (2001). Molecular cloning of the CA125 ovarian cancer antigen: identification as a new mucin, MUC16. J. Biol. Chem. 276, 27371-27375.
54. Yin, B.W.T., Dnistrian, A., and Lloyd, K.O. (2002). Ovarian cancer antigen CA125 is encoded by the MUC16 mucin gene. Int. J. Cancer 98, 737-740.
55. Zeimet, A.G., Marth, C., Offner, F.A., Obrist, P., Uhl-Steidl, M., Feichtinger, H., Stadlmann, S., Daxenbichler, G., and Dapunt, O. (1996). Human peritoneal mesothelial cells are more potent than ovarian cancer cells in producing tumor marker CA-125. Gynecol. Oncol. 62, 384-389.